Fast Five Quiz: Non–Small Cell Lung Cancer (NSCLC) Targeted Therapy

Winston Tan, MD

Disclosures

October 22, 2021

More than 80% of all lung cancers are non–small cell lung cancers (NSCLCs), and roughly half of these cancers harbor oncogenic driver mutations. Several agents that target some of these molecular aberrations are now available for the treatment of NSCLC, leading to a new era in the care of patients with these cancers.

How much do you know about targeted therapy for NSCLC? Test your knowledge with this quick quiz.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....